Watertown, Mass., April 17, 2026 Globe Newswire -- Lyra Therapeutics, Inc. the Company today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commissio
Why Is Lyra Therapeutics, Inc. (LYRA) Stock Down Today?
Updated Nov 17, 2026 2:49 PM ET · Prev Close $1.32
This stock is down 62% today — a major single-session selloff. Confirm volume stabilization and key support defense before entering.
Session Regime & Catalyst Assessment
68% Signal ConvictionLyra Therapeutics, Inc. Pulling Back 62.50% on 1.00x Relative Volume
Lyra Therapeutics, Inc. (LYRA) is pulling back 62.50% (-$0.83) to $0.49 on 1.00x average session volume. Relative to benchmarks, LYRA is lagging the S&P 500 by -61.16%. 14-day RSI stands at 21.5, keeping momentum in a oversold regime.
Watertown, Mass., April 17, 2026 Globe Newswire -- Lyra Therapeutics, Inc. the Company today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commissio
Price ($0.49) trades relative to 20-day SMA ($1.27) and 50-day SMA ($1.82).
Market & Sector Relative Strength
LYRA lagging the S&P 500 by -61.16%Options Flow & Execution Desk
Recent LYRA Catalyst Headlines
Verified WireLyra Therapeutics LYRA , announced that its Board of Directors has decided to suspend further development of Lyr-210, the Company s lead product candidate for the treatment of chronic rhinosinusitis. The Company also ann
Watertown, Mass., Jan. 12, 2026 Globe Newswire -- Lyra Therapeutics, Inc. Nasdaq LYRA Lyra or the Company today announced that its Board of Directors has decided to suspend further development of Lyr-210, the Company s l
Company plans new, confirmatory Phase 3 clinical trial of Lyr-210 for treatment of chronic rhinosinusitis CRS without nasal polyps, on path to NDA submission Watertown, Mass., Nov. 12, 2025 Globe Newswire -- Lyra Therape
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.48 (session support) for directional breakout confirmation.
Technical Regime (LYRA)
BEARISH MA TRENDRetail & Crowd Sentiment
NeutralNegative sentiment prevails on $LYRA as delisting and appeal rejection messages circulate on StockTwits, with no positive news articles to offset the bearish tone.
About Lyra Therapeutics, Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT …
Get Instant LYRA Catalyst Alerts
Receive an email alert when LYRA triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversLYRA Session & Catalyst FAQ
Why is LYRA stock down today?
Lyra Therapeutics, Inc. (LYRA) is pulling back 62.50% (-$0.83) to $0.49 on 1.00x average session volume. Relative to benchmarks, LYRA is lagging the S&P 500 by -61.16%. 14-day RSI stands at 21.5, keeping momentum in a oversold regime.
Is LYRA stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.00x relative volume (moderate participation). Our multi-factor model currently rates LYRA as HOLD. Review full valuation, quality, and timing signals on the LYRA Buy or Sell Decision Brief →
What is LYRA's intrinsic value and expected trading range?
At $0.49, LYRA's modeled 1-to-3 session range is $0.46 – $0.52, with a key inflection level at $0.48 (session support). Compare current price against multi-year cash flow projections in the LYRA Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for LYRA?
RSI at 21.5 indicates oversold conditions — watch for mean-reversion support. LYRA trades at $0.49 relative to its 20-day SMA ($1.27) and 50-day SMA ($1.82), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.